TP53 and neoplasm: In in vivo experiments using an AOM/DSS-induced CRC model, the HP (1.14–4.56 g/kg) dose significantly inhibited tumor formation while upregulating key molecules of the p53/p21 signaling pathway (Li J. et al., 2023).